BofA lowered the firm’s price target on Karuna Therapeutics to $259 from $304 and keeps a Buy rating on the shares after offering updated views on key investor debates within the analyst’s CNS coverage. On further review, the firm says its prior Karuna KarXT schizophrenia forecasts were “too high,” but adds that it still views $3B in peak sales as “feasible” given the strength of the profile.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on KRTX:
- Karuna Therapeutics initiated with an Overweight at Wells Fargo
- Karuna Therapeutics price target lowered to $258 from $274 at Mizuho
- Karuna Therapeutics names Jason Brown as CFO, Jonathan Rosin as CHRO
- Karuna Therapeutics reports Q2 EPS ($2.75), consensus ($2.78)
- 3 Best Stocks to Buy Now, 7/20/2023, According to Top Analysts